ELAB - Company ID 0001840563
Elevai Labs Inc. trades as ELAB. In its fiscal 2025 annual report the company posted revenue of $590.08K, down 65.5% from the prior year and net income of -$7.75M. This page tracks Elevai Labs Inc. through 252 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Net profit margin compressed from -234.9% to -1313.0% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-27 |
| Proxy statement | DEF 14A | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-15 |
| Major company event | 8-K | 2026-05-13 |
| PRE 14A | - | 2026-05-04 |
| DEF 14C | - | 2026-05-04 |
| Major company event | 8-K | 2026-04-28 |
| DEF 14C | - | 2026-04-27 |
The largest companies sharing Elevai Labs Inc.'s SEC industry classification (pharmaceutical preparations).
Elevai Labs Inc. reported revenue of $590.08K for fiscal year 2025, a decrease of 65.5% year over year.
In its latest fiscal year Elevai Labs Inc. reported a net loss of $7.75M.